TMCnet News
Stocks That Stand Out For Nov. 20th, 2009 Are ARTS, CCTR, KNDR, GETA(M2 PressWIRE Via Acquire Media NewsEdge) www.Standoutstocks.com: Stocks That Standout For Nov. 20th, 2009 are Artfest International, Inc. (OTCBB: ARTS), China Crescent Enterprises, Inc. (OTCBB: CCTR), Kender Energy Inc. (PINKSHEETS: KNDR), Genta Incorporated (OTCBB: GETA) Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com _________________________________________________ Artfest International, Inc. Posts Net Profit for the Third Quarter 2009 Company Files Its 10Q With the SEC for the Third Quarter Ending September 30, 2009 DALLAS, TX, Nov 20, 2009 -- Artfest International, Inc. (OTCBB: ARTS) is pleased to announce that the Company has generated $896,404 in operating revenue in the third quarter ending September 30, 2009 as compared to $4,000 in operating revenue for the third quarter ending September 30, 2008, which is an increase of 22,310%. Artfest International, Inc. also reported net income of $7,397 for the third quarter ending September 30, 2009 versus a loss of $29,862 for the same period in 2008. The increase in operating revenue is due to the increased sales of art and sports memorabilia through the Company's wholly owned subsidiary, Charity Sports Distributor, as well as through events held at Artfest International's 52,000 square foot facility in Dallas, Texas, and direct sales activity through its Art Channel, Inc. and Art Channel Galleries, Inc. subsidiaries. Artfest International reported total assets of $3,421,019 for the third quarter ending September 30, 2009 as compared to $537,445 for the third quarter ended September 30, 2008, which is a 536% increase. Based on Artfest's direct sales model, combined with the acquisition of CSD, Art Channel Galleries increased its sales due to the addition of sports and memorabilia territory right, which created sales to its new members during the third quarter. CSD, which accounted for nearly half of Artfest International's third quarter revenue, is a vertically integrated custom framing company that specializes in the design, production and distribution of authentic framed autographed sports and entertainment collectibles and art pieces. CSD's distribution avenues include business to business (B2B) and business to consumer (B2C) sales, charity fundraising auctions, professional and college sports teams' pro shops, e-stores, online auctions and a revolutionary in-game silent auction concept known as Home Game Auction. The relationship with Artfest International has enabled CSD to expand its business model during the third quarter beyond its home game auction relationship with the 13 professional and college teams, with the signing of an agreement with Jump TV USA Holding Company to provide major college alumni player autographed memorabilia for Jump TV's online auctions. CSD recently solidified its partnership with NeuLion, (formerly Jump TV) to target the $1 Billion online sports auction market. CSD and NeuLion jointly host bi-weekly auctions for sports teams, which include The Ohio State University and The University of Georgia amongst others. During the third quarter, Artfest International also diversified its overall product line by signing an agreement with Nature's Sleep, Inc. and Mattress 4 You to distribute Nature's Sleep's Visco Memory Foam Mattress. The Company will assume the responsibility for the production of a Nature's Sleep Visco Memmory Foam mattress Infomercial. "We are excited about the progress that Artfest International has made during the third quarter and we look forward to continuing to increase shareholder value through strengthening our relationships with both artists and sports teams in order to increase sales of our artwork and sports memorabilia," stated Edward Vakser, CEO of Artfest International, Inc. Artfest International's Third Quarter 10-Q can be found at: www.sec.gov. About Artfest International, Inc. Artfest International, Inc. brings together artists, investors, decorators, designers, private collectors and art galleries. Artfest International's corporate site is www.artfestinternational.com. Artfest's subsidiaries are Art Channel, Inc. (www.artchannel.tv), and Art Channel Galleries, Inc. (www.ArtChannelGalleries.com), offering the most exciting product and rewards program in the history of direct sales marketing. Safe Harbor Statement -- This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual or future results may differ materially from those anticipated depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ARTI does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. This press release contains "forward-looking" statements. These statements involve risk and uncertainties that could cause actual results to differ materially. There is no assurance the above described transaction will be completed. There can be no assurance of the ability of the company to achieve sales goals, obtain contracts or financing, consummate acquisitions or achieve profitability in the future. The above and additional factors are discussed in detail in the company's filings with the SEC or found on www.pinksheets.com. China Crescent Enterprises, Inc. Reports Record $1.8 Million in Net Income on $30 Million in Revenue for the Nine Months Ending September 30, 2009 DALLAS, TX, Nov 20, 2009 -- China Crescent Enterprises, Inc. (OTCBB: CCTR) has filed its third quarter 2009 financial results on SEC Form 10-Q. The Company reported $30 million in revenue through the nine months ending September 30, 2009 and a record net income of $1.8 million compared to $517k in net income for the same period in 2008. The Company has forecasted profitable revenue growth in 2009 compared to 2008. The Company reported over $40 million in profitable revenue in 2008. Webcast to Review Q3'09 Results China Crescent is scheduled to release an on-demand Webcast later today to review the Company's 3rd quarter financial report. A link to the on-demand Webcast is scheduled to be posted to the corporate website homepage www.chinacrescent.com upon release. Sign Up to Receive Regular China Crescent Investor Updates China Crescent sends regular email updates to its opt-in, permission-based email database. Interested investors can easily, safely and quickly register to receive these communications directly on the corporate website homepage (www.chinacrescent.com). Recipients can manage their own email contact profile and safely unsubscribe at any time. About China Crescent Enterprises, Inc. (www.chinacrescent.com) China Crescent Enterprises, Inc. reported over $40 million in profitable revenue in 2008. The Company is a technology leader in the rapidly developing Chinese market specializing today in software engineering, high quality software development and digital multimedia outsourcing services delivered to customers globally. At the same time, the firm is a systems integrator and value added reseller of major global hardware brands in the Chinese domestic market. Headquartered in Dallas with operations in Shanghai and Beijing, China Crescent bridges the gap between Western and Eastern business cultures to assist Western clients in realizing the advantages of the high quality, low cost technology products and services available from China. China Crescent also assists Western clients in localizing products and services to realize the tremendous growth potential available by expanding into the Chinese Market. "SAFE HARBOR STATEMENT" UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements that involve risks and uncertainties. The statements in this release are forward-looking statements that are made pursuant to safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results, events and performance could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause China Crescent's actual results in future periods to differ materially from results expressed or implied by forward-looking statements. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making investment decisions. Kender Energy Signs Malta LOI Agreement for 1000 Units Minimum Annually Sales Commitment for Its Solar Technology, With Markets in Over a Dozen Countries GENEVA, Nov 19, 2009 -- Kender Energy Inc. (PINKSHEETS: KNDR) today announced that it has signed a Letter of Intent (LOI) with Malta Licensing & Distribution Network S.A. (MLDN), a Maltese based international distributor with exposure into over 12 countries world-wide. The earlier discussions with Malta Licensing & Distribution Network have resulted in an increase from the original 500 units per year to 1000 units per year minimum sales, in the definitive Letter of Intent (LOI). "With distribution into North Africa, Greece, Turkey, the Middle East and the UAE the LOI agreement with Malta Licensing will accelerate our growth into these very important international markets," stated Sean Kelly, President and CEO of Kender Energy Inc. Mr. Kelly further states, "We welcome Malta Licensing and Distribution on the Kender Energy team with the goal to further populate the international world with our cutting edge solar technology." About Kender Energy Inc.: Kender Energy Inc. is a development phase company active in the field of solar energy. Its present prototypes of solar panels are being developed into a full-scale solar energy production system. The particularity of the Kender solar panel system and technology is to allow, via a closed circuit of gas (usually helium), to create a heat exchange with the sunlight and the air from the environment. The exchange generates the spinning of the helium gas in the closed circuit, propelling a turbine, which produces electricity in a 100% clean and renewable process. The system's main advantages are that it is efficient, cheap in production, and modular. The company is based near Geneva, Switzerland. Its Website is www.kendersolar.com. Safe Harbor Statement: All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma Data Presented at International Melanoma Conference in Berlin BERKELEY HEIGHTS, N.J., Nov 20, 2009 -- --Results Follow Decision by Company to Continue Phase 3 AGENDA Trial for Overall Survival Genta Incorporated (OTCBB: GETA.OB) announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. The data were featured this week in a presentation at the annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany. Based on preclinical evidence of synergy, this study combined Genasense with temozolomide (Temodar(R); Schering Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles for injectable suspension [albumen bound]; Abraxis Bioscience, Inc.). Previous results using a standard dose and schedule of Genasense (i.e., approximately 500 mg infused over 24 hours daily for 7 days) suggested this investigational combination was associated with clinical activity and good tolerability in 18 patients. In the new schedule, Genasense was administered with the same chemotherapy as a brief IV infusion over 1-hour twice per week for 4 consecutive weeks at a dose of 900 mg. This schedule compresses approximately 48 hours of standard dosing into a brief 1-hour infusion. To date, 10 patients with Stage IV metastatic melanoma have been accrued to this ongoing trial. Three patients achieved confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 to 40 weeks. One patient has maintained stable disease that has lasted 16 weeks, two patients have progressed, and four patients are too early to evaluate, having received only a single cycle. Only one episode (i.e., Grade 3 neutropenia) of any Grade 3-4 adverse event has been observed. "With a preliminary disease control rate (defined as complete or partial responses plus stable disease lasting at least 3 months) of 67%, we view these data as very promising," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development. "Temozolomide is the active metabolite of dacarbazine that has been used in our Phase 3 trial in patients with advanced melanoma. I am pleased to confirm that Genta will continue the Phase 3, randomized, double-blind AGENDA trial in order to determine overall survival in that study. Finally, taxanes are being increasingly used in patients with metastatic melanoma. We intend to initiate a Phase 2 study of our proprietary oral taxane, tesetaxel, in advanced melanoma. We hope our comprehensive approach with these new medicines may improve the management of this devastating disease." About the AGENDA trial in advanced melanoma Genta has completed enrollment into AGENDA, a Phase 3, randomized, double-blind, placebo-controlled trial of Genasense in patients with advanced melanoma. Initial results did not show statistically significant differences in overall response or progression-free survival. The endpoints of durable response (complete or partial response lasting greater-than or equal to 6 months) and overall survival are too early to evaluate. An analysis for futility has been conducted for the survival endpoint, and the trial has passed that analysis. The Company has announced it plans to continue to follow patients on AGENDA in order to determine this endpoint. About the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers This international conference is organized annually by the European Association of Dermatologic Oncology (EADO), which is a co-leader of the AGENDA trial. The meeting offers melanoma clinicians and researchers from multidisciplinary melanoma/skin cancer centers an opportunity to interact, establish collaborations, and set an agenda for the further evolution of melanoma care and research. Genta is a Co-Sponsor of the EADO meeting. About Melanoma Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the U.S. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation: http://www.melanoma.org. About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta has pursued a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer. About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed oral formulations of the active ingredient in Ganite, which have completed preliminary clinical trials, as a potential treatment for diseases associated with accelerated bone loss. The Company is developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta intends to evaluate the clinical activity of tesetaxel in a range of human cancers. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com. Safe Harbor This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: -- the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency; -- the safety and efficacy of the Company's products or product candidates; -- the commencement and completion of any clinical trials; -- the Company's assessment of its clinical trials; -- the Company's ability to develop, manufacture, license, or sell its products or product candidates; -- the Company's ability to enter into and successfully execute any license and collaborative agreements; -- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, the Company's ability to obtain sufficient financing to fund the AGENDA trial, or the Company's risk of bankruptcy; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q. About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button. Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market. Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |